Ma Weijie, Wu Long, Zhou Fuling, Hong Zhenfei, Yuan Yufeng, Liu Zhisu
Cell Physiol Biochem. 2017;41(2):609-622. doi: 10.1159/000457883. Epub 2017 Feb 3.
Hepatocellular carcinoma (HCC) is one of the most common malignant diseases worldwide with limited therapeutic options. Accumulating evidences suggest that immunotherapy could be a promising option for treating HCC. T cell-associated immunotherapy lights up the hope for the improvement of complementary approach to conventional HCC treatments, which needs further research to consummate the clinical consequences. The present work reviewed several T cells associated cellular immunotherapies for HCC, including immune checkpoint blockade, gene-engineered T cells, bispecific T cell engagers, and so on. We also analyzed how these immunotherapies can mediate tumor cell eradication and evaluated their superiority or insufficiency.
肝细胞癌（HCC）是全球最常见的恶性疾病之一，治疗选择有限。越来越多的证据表明，免疫疗法可能是治疗HCC的一个有前景的选择。T细胞相关免疫疗法为改进传统HCC治疗的补充方法带来了希望，这需要进一步研究以完善临床疗效。本研究综述了几种用于HCC的T细胞相关细胞免疫疗法，包括免疫检查点阻断、基因工程T细胞、双特异性T细胞衔接器等。我们还分析了这些免疫疗法如何介导肿瘤细胞清除，并评估了它们的优势或不足。
